Idexx Laboratories (IDXX)

• Market cap: $35.4B
• 1 day: 2.51%
• 5 days: 7.86%
• 1 month: 3.24%
• 3 months: 0.46%
• 6 months: -3.31%
• Year to date: 6.96%
• 1 year: -11.52%
• 5 years: 60.90%
• 10 years: 433.12%
• Sector: Healthcare
• Industry: Diagnostics & Research

About: Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 35% of its revenue from outside the United States.

Employees: 11,000

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

14% more first-time investments, than exits

New positions opened: 158 | Existing positions closed: 139

0% more funds holding

Funds holding: 1,099 [Q3] → 1,100 (+1) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 12 [Q3] → 12 (+0) [Q4]

0.27% less ownership

Funds ownership: 87.79% [Q3] → 87.52% (-0.27%) [Q4]

18% less capital invested

Capital invested by funds: $36.2B [Q3] → $29.7B (-$6.51B) [Q4]

23% less repeat investments, than reductions

Existing positions increased: 334 | Existing positions reduced: 432

44% less call options, than puts

Call options by funds: $71.7M | Put options by funds: $129M

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $420 4% downside
• Avg. target: $507 16% upside
• High target: $550 26% upside

5 analyst ratings

• positive: 2 40%
• neutral: 3 60%
• negative: 0 0%

Stifel Jonathan Block 10% 1-year accuracy 2 / 20 met price target	4% downside $420	Hold Maintained	14 Apr 2025
Piper Sandler David Westenberg 43% 1-year accuracy 18 / 42 met price target	17% upside $510	Neutral Maintained	10 Feb 2025
Barclays Balaji Prasad 19% 1-year accuracy 8 / 43 met price target	19% upside $520	Overweight Maintained	4 Feb 2025
B of A Securities Michael Ryskin 60% 1-year accuracy 3 / 5 met price target	22% upside $535	Neutral Maintained	4 Feb 2025
Morgan Stanley Erin Wright 44% 1-year accuracy 11 / 25 met price target	26% upside $550	Overweight Maintained	29 Jan 2025